Brivanib

CAS : 649735-46-6

Ref. 3D-FB103852

Informations sur le produit

• Nom: Brivanib
• Synonymes: (2R)-1-[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol, (2R)-1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol, 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)-, Bms-540215, Ptk787, Vatalanib

Description

Brivanib is a drug that belongs to the class of inhibitors. It was developed as an oral prodrug, brivanib alaninate, which is enzymatically cleaved to release brivanib. Brivanib inhibits human tyrosine kinases, including BCR-ABL and c-KIT. Brivanib has shown efficacy in inhibiting the growth of solid tumours in vivo. The molecular mechanisms underlying its anti-cancer properties are not fully understood, but it has been shown to inhibit cancer cell proliferation and induce apoptosis. Brivanib has also been shown to bind with high affinity to human plasma proteins and inhibit the binding of ADP-ribosylation factor (ARF) to its substrates.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 370.38 g/mol
• Formule: C₁₉H₁₉FN₄O₃
• Degré de pureté: Min. 95%
• Couleur/Forme: Powder
• InChI: InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
• Code InChI: InChIKey=WCWUXEGQKLTGDX-LLVKDONJSA-N
• SMILES: Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1